We are live on ! Find out more

Geron

GERN

Market cap $970M

1.51 USD

-0.02

1.31%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

1.51

0.00

0%

1 day

-1.31%

5 days

-1.31%

1 month

4.14%

3 months

20.8%

6 months

-2.58%

Year to date

14.39%

1 year

5.59%

5 years

4.86%

10 years

-43.23%

About: Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Employees: 258

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 23.5%

Neutral 70.6%

Negative 5.9%

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the mid- to high-end of that guidance. A potential competitor in myelofibrosis, KPTI, is looking to file for approval in frontline myelofibrosis, while GERN is running its phase 3 study in relapsed/refractory myelofibrosis.

Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis

Geron Corporation (GERN) Q2 2026 Earnings Call Transcript

Geron Corporation (GERN) Q2 2026 Earnings Call Transcript

Geron Corporation (GERN) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates

Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.

Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates

Geron Q2 Earnings Call Highlights

Geron NASDAQ: GERN reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS.

Geron Q2 Earnings Call Highlights

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Achieved $57.5 million in RYTELO ® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Officer Company to host conference call and webcast today, August 5, 2026, at 8:00 a.m. ET FOSTER CITY, Calif.

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Price charts implemented using Lightweight Charts™